655 related articles for article (PubMed ID: 32787587)
21. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
22. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
23. An update on colorectal cancer microenvironment, epigenetic and immunotherapy.
Jin K; Ren C; Liu Y; Lan H; Wang Z
Int Immunopharmacol; 2020 Dec; 89(Pt A):107041. PubMed ID: 33045561
[TBL] [Abstract][Full Text] [Related]
24. T-cell-based immunotherapy in colorectal cancer.
Feng M; Zhao Z; Yang M; Ji J; Zhu D
Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy and immunoevasion of colorectal cancer.
Al Zein M; Boukhdoud M; Shammaa H; Mouslem H; El Ayoubi LM; Iratni R; Issa K; Khachab M; Assi HI; Sahebkar A; Eid AH
Drug Discov Today; 2023 Sep; 28(9):103669. PubMed ID: 37328052
[TBL] [Abstract][Full Text] [Related]
26. Complement System: An Immunotherapy Target in Colorectal Cancer.
Talaat IM; Elemam NM; Saber-Ayad M
Front Immunol; 2022; 13():810993. PubMed ID: 35173724
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress.
Rastin F; Javid H; Oryani MA; Rezagholinejad N; Afshari AR; Karimi-Shahri M
Int Immunopharmacol; 2024 Jan; 126():111055. PubMed ID: 37992445
[TBL] [Abstract][Full Text] [Related]
28. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
Kishore C; Bhadra P
Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
[TBL] [Abstract][Full Text] [Related]
29. Novel avenues in immunotherapies for colorectal cancer.
Pardieck IN; Jawahier PA; Swets M; van de Velde CJ; Kuppen PJ
Expert Rev Gastroenterol Hepatol; 2016; 10(4):465-80. PubMed ID: 26582071
[TBL] [Abstract][Full Text] [Related]
30. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
31. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer.
Dmello RS; To SQ; Chand AL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669775
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Immunotherapy in Microsatellite-Instability High Nonmetastatic Colorectal Cancer: A Single-institute Experience and Review of the Literature.
Kinney RE; Khalil M
Clin Colorectal Cancer; 2021 Jun; 20(2):e109-e112. PubMed ID: 33722513
[No Abstract] [Full Text] [Related]
34. The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M; Carethers JM
Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
[No Abstract] [Full Text] [Related]
35. The evolving role of immune oncology in colorectal cancer.
Dawood S
Chin Clin Oncol; 2018 Apr; 7(2):17. PubMed ID: 29764162
[TBL] [Abstract][Full Text] [Related]
36. Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy.
Alzamami A
Med Oncol; 2023 Nov; 40(12):352. PubMed ID: 37950801
[TBL] [Abstract][Full Text] [Related]
37. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
38. Optimizing immunotherapy for colorectal cancer.
Ganesh K
Nat Rev Gastroenterol Hepatol; 2022 Feb; 19(2):93-94. PubMed ID: 34907331
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for colorectal cancer.
Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H
World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
